Mumbai: AstraZeneca Pharma India Ltd reported a profit after tax of ₹51 crore, down 10% YoY, in the September quarter of FY25.

The pharmaceutical major announced a 31% increase in its operational turnover compared to last year. ₹408 million.

The company’s growth was driven by its product portfolio in the oncology, biopharmaceuticals and rare disease segments, Bhavana Agrawal, the company’s chief financial officer, said in a statement on Wednesday.

“The company’s growth stems from our ambition to bring innovative medicines into the country faster to address unmet patient needs,” she said.

The Indian arm of the Anglo-Swedish pharmaceutical manufacturer recently announced the launch of several new products. Palivizumab, also known by the brand name Synagis, used to prevent severe lower respiratory illness caused by respiratory syncytial virus (RSV) in high-risk children, was launched in October 2024.

The company had announced the launch in September after receiving import and marketing clearance in September 2023 from the Drug Controller General of India (DGCI).

Read also | Hypertension, diabetes medicines among top-selling medicines at Janaushadhi Kendras this year

The pharmaceutical company also launched Tremelimumab (Imjudo), a drug used to treat certain types of cancer.

It received approval to sell and distribute its drug durvalumab (Imfinzi) from the Central Pharmaceutical Standards Control Organization. Durvalumab in combination with chemotherapy and as monotherapy after surgery is used to treat resectable tumors 4 cm or larger and node-positive lung cancer or lymph node cancer in patients.

“We are constantly working towards expanding access to innovative therapies, progressive access strategies and making healthcare systems resilient in India,” said Sanjeev Panchal, Country President and Managing Director, AstraZeneca Pharma India Ltd.

During the first half of this financial year, the company reported consolidated revenue of ₹795.5 crore, a growth of 31% over H1FY24.

The company’s shares closed at ₹7,194 each at the National Stock Exchange today, down 2.84% from the previous close.